GSK to Nearly Double Cancer Drugs in Trials Next Year, WSJ Reports
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Huarong Energy to Be Delisted From November 3
Huarong Energy will lose its listing status from November 3.
M impact | EQUITY | Oct 30, 2026, 02:05 AM UTC
CEPCO Seeks Approval for Buyback of Up to 10% of Shares
CEPCO will seek shareholder approval for the buyback.
M impact | EQUITY | Oct 30, 2026, 02:05 AM UTC
Vale Q3 Profit Tumbles as Iron Ore Output Misses Forecasts
Vale’s adjusted EBITDA was in line.
M impact | EQUITY | Oct 30, 2026, 02:04 AM UTC
Taiwan's Taiex Falls 3.0% to 44983.64
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
SAIC Motor Shares Fall 5.9% as Q3 Profit Plunges
SAIC Motor shares fell 5.9% in early trading to a two-month low. The automaker reported third-quarter net profit on Thursday.
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
Boston Scientific Reports Q3 Sales of $5.138 Billion, Lowers 2026 EPS Guidance
Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5% year over year, and adjusted EPS of $0.73. It lowered full-year adjusted EPS guidance to $3.16–$3.18, citing Chi
M impact | EQUITY | Oct 30, 2026, 02:02 AM UTC